Telmisartan Teva

RSS

telmisartan

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Telmisartan Teva has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 17/09/2021

Authorisation details

Product details
Name
Telmisartan Teva
Agency product number
EMEA/H/C/001146
Active substance
Telmisartan
International non-proprietary name (INN) or common name
telmisartan
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09CA07
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva B.V.
Revision
11
Date of issue of marketing authorisation valid throughout the European Union
25/01/2010
Contact address

Swensweg 5
2031GA Haarlem
The Netherlands

Product information

09/02/2021 Telmisartan Teva - EMEA/H/C/001146 - IA/0027

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension in adults

Assessment history

Related content

How useful was this page?

Add your rating